Autopsy report · NCT02671955

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

“Janssen business decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Janssen Research & Development, LLC

Sponsor type

Industry

Conditions

Advanced Cancer

Interventions

JNJ-61610588

Participants

12

Sites

4

Countries

United States

Trials that died the same way

• A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
  “Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.” (61% match in meaning)
• Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
  “Business Decision” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.